Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
NEW YORK, Dec. 23, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Arrowhead Pharmaceuticals, Inc. securities (NASDAQ:ARWR) from May 11, 2015 through November 8, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Arrowhead investors under the federal securities laws.
To join the Arrowhead class action, go to http://www.rosenlegal.com/cases-997.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants made materially false and misleading statements and/or failed to disclose that: (1) ARC-520, one of Arrowhead’s drug candidates for patients with chronic hepatitis B infection, was fatal at certain doses; (2) consequently, the U.S. Food & Drug Administration was unlikely to approve ARC-520 as a hepatitis B treatment; (3) Arrowhead had overstated the approval prospects and commercial viability of ARC-520; and (4) as a result, Arrowhead’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-997.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
